Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
UCAN is a private consumer health and sports nutrition company that markets steady-release energy, hydration, and protein products built around its patented LIVSTEADY carbohydrate technology. The company traces its origin to the development of a specialized carbohydrate intended to help a child with glycogen storage disease avoid dangerous blood sugar drops, and it has since expanded into endurance and active-nutrition markets. UCAN's commercial portfolio includes energy gels, drink mixes, electrolyte products, bars, and protein formulations designed to provide sustained energy without large glucose spikes or heavy sugar loads. While it is healthcare-adjacent and science-driven, UCAN is not a drug-development biotech or pharmaceutical company and does not appear to operate a therapeutic clinical pipeline. Its business is best characterized as commercial nutrition and metabolic-performance products rather than therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ucan Products.